Department of Oncology Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co. Ltd, Shanghai, China;Department of Research & Development, Jiangsu Hengrui Pharmaceuticals Co. Ltd, Shanghai, China
Auto-generated profile, based on publicly available information
Lianshan Zhang
Department of Oncology Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co. Ltd, Shanghai, China;Department of Research & Development, Jiangsu Hengrui Pharmaceuticals Co. Ltd, Shanghai, China
Introduction: CD73 and adenosine support growth-promoting neovascularization, metastasis, and survival in cells, and promote anti-PD-1 mAb therapy-induced immune escape. Consequently, developing a CD73 inhibitor as monotherapy and a potential beneficial combination partner with immune-checkpoint inhibitors needs investigation. Methods: CD73 inhibitors were evaluated in vitro with soluble and membrane-bound CD73 enzymes, as well as its PD biomarker responses in human peripheral blood mononuclear cells (PBMC) by flow cytometry and ELISA. The binding modes of the molecules were analyzed via molecular modeling. The anti-tumor activity and synergistic effect of SHR170008 in combination with anti-PD-1 mAb were evaluated in a syngeneic mouse breast cancer model. Results: SHR170008 was discovered during the initial structural modifications on the link between the ribose and the α-phosphate of AMPCP, which significantly improved the stability of the compound confirmed by the metabolite identification study. Further modifications on the adenine base of AMPCP improved the potency due to forming stronger interactions with CD73 protein. It exhibited potent inhibitory activities on soluble and endogenous membrane-bound CD73 enzymes, and induced IFNγ production, reversed AMP-suppressed CD25+ and CD8+/CD25+ expression, and enhanced granzyme B production on CD8+ T cells in human PBMC. SHR170008 showed dose-dependent anti-tumor efficacy with suppression of adenosine in the tumors in EMT6 mouse breast tumor model. The increase of adenosine in tumor tissue by anti-PD-1 mAb alone was suppressed by SHR170008 in the combination groups. Simultaneous inhibition of CD73 and PD-1 neutralization synergistically enhanced antitumor immunity and biomarkers in response, and exposures of SHR170008 were correlated with the efficacy readouts. Conclusion: Our findings suggest that CD73 may serve as an immune checkpoint by generating adenosine, which suppresses the antitumor activity of anti-PD-1 mAb, and inhibition of CD73 may be a potential beneficial combination partner with immune-checkpoint inhibitors to improve their therapeutic outcomes in general.
24 February 2022 in European Journal of Pharmaceutics and Biopharmaceutics
Epitope mapping of the interactions between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Abs is challenging because of complexity in protein three-dimensional structures. Protein structure fingerprint technology was applied for epitope mapping of 44 SARS-CoV-2 Abs with three-dimensional structure complexes. The results defined how the epitopes were distributed on SARS-CoV-2 and how the patterns of six CDRs from Abs participated in neutralization. Also, the residue–residue recognition revealed that certain residues had higher frequencies on the interfaces between SARS-CoV-2 and Abs, and the activity correlated with the physicochemical properties of the residues at the interface. Thus, epitope mapping provides significant lead information for development of epitope-based designs for Abs, vaccines, and diagnostic reagents. This is a bioinformatics project of structural data analysis; no animals or cells were used.
3 December 2025 in International Journal of Clinical Oncology and Cancer Research
Background: In recent years, the therapeutic landscape for cancer patients has undergone a profound transformation with the emergence of third-generation HER2-targeted ADCs, including T-DXd and SHR-A1811. Nevertheless, recurrence and metastasis are inevitable for most patients, and the mechanisms driving resistance to these ADCs remain poorly understood. Against this backdrop, the present study seeks to elucidate the resistance mechanisms of breast cancer cells to SHR-A1811 and T-DXd, while identifying potential targets to enhance sensitivity to these agents. Methods: Two resistant cell lines-SHR-A1811-resistant and T-DXd-resistant-were established from the parental breast cancer JIMT-1 cell line via successive drug administration. To identify alterations in protein expression profiles, label-free liquid chromatography-tandem mass spectrometry (LC-MS/MS) and single-cell RNA sequencing (scRNA-seq) were employed. Validation of the findings was performed using Western blotting, RNA interference, transfection, and the CellTiter-Glo (CTG) Luminescent Cell Viability Assay. Results: A total of 5,664 differentially expressed proteins were quantitatively identified via proteomic analysis comparing SHR-A1811/T-DXd-resistant cells with their sensitive counterparts. Integrated proteomic and scRNA-seq analyses revealed significant up-regulation of CD44 and PLOD2 in resistant cells. Subsequent validation studies confirmed that CD44 expression was substantially higher in both resistant cells relative to their sensitive counterparts, and CD44 knockdown enhanced the sensitivity of the resistant cells to the ADCs. Conclusions: Our findings demonstrate that CD44 is a critical factor in the development of resistance to SHR-A1811 and T-DXd, with potential utility as both a resistance biomarker for third-generation HER2-ADCs in breast cancer and a therapeutic target to overcome such resistance.